Literature DB >> 20536469

Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4.

Steven P Dunn1, David G Heidemann, Christopher Y C Chow, David Crockford, Nabila Turjman, Janet Angel, Christian B Allan, Gabriel Sosne.   

Abstract

Neurotrophic corneal defects are difficult to heal and all too often lead to scarring and vision loss. Medical management is often of limited success. We describe the results of nine patients (ages 37-84) with chronic nonhealing neurotrophic corneal epithelial defects who were treated with thymosin beta 4 (Tbeta4) sterile eye drops for 28 or 49 days with a follow-up period of 30 days. Those with geographic defects (six patients) showed dramatic healing without clinically significant neovascularization. Stromal thinning was observed in one patient. Three patients with punctate epithelial defects did not have a demonstrable change in their clinical findings. Reduced ocular irritation was reported by all patients soon after treatment initiation. Results from these compassionate use cases indicate that Tbeta4 may provide a novel, topical approach to wound healing in chronic nonhealing neurotrophic corneal ulcers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20536469     DOI: 10.1111/j.1749-6632.2010.05471.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  19 in total

Review 1.  Thymosin beta 4 regulation of actin in sepsis.

Authors:  Justin B Belsky; Emanuel P Rivers; Michael R Filbin; Patty J Lee; Daniel C Morris
Journal:  Expert Opin Biol Ther       Date:  2018-03-06       Impact factor: 4.388

Review 2.  Progress in corneal wound healing.

Authors:  Alexander V Ljubimov; Mehrnoosh Saghizadeh
Journal:  Prog Retin Eye Res       Date:  2015-07-18       Impact factor: 21.198

3.  Anti-inflammatory and anti-apoptotic effects of N-acetylcysteine in diabetic rat corneal epithelium.

Authors:  Sae-Byeok Hwang; Jin Hyoung Park; Ji-Yun Park; Soon-Suk Kang; Ho Seok Chung; Hun Lee; Jae Yong Kim; Hungwon Tchah
Journal:  Int J Ophthalmol       Date:  2021-12-18       Impact factor: 1.779

4.  Efficacy of treatments for neurotrophic keratopathy: a systematic review and meta-analysis.

Authors:  Sébastien Roumeau; Frédéric Dutheil; Vincent Sapin; Julien S Baker; Stephanie L Watson; Bruno Pereira; Frédéric Chiambaretta; Valentin Navel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-07       Impact factor: 3.535

5.  Thymosin β4 overexpression regulates neuron production and spatial distribution in the developing avian optic tectum.

Authors:  Mael Lever; Carsten Theiss; Gabriela Morosan-Puopolo; Beate Brand-Saberi
Journal:  Histochem Cell Biol       Date:  2016-12-10       Impact factor: 4.304

6.  Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.

Authors:  Gabriel Sosne; George W Ousler
Journal:  Clin Ophthalmol       Date:  2015-05-20

Review 7.  Diagnosis and management of neurotrophic keratitis.

Authors:  Marta Sacchetti; Alessandro Lambiase
Journal:  Clin Ophthalmol       Date:  2014-03-19

Review 8.  Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease.

Authors:  Yong Jiang; Tao Han; Zhi-Guang Zhang; Man Li; Feng-Xiang Qi; Ying Zhang; Ying-Lan Ji
Journal:  Chronic Dis Transl Med       Date:  2017-07-08

Review 9.  Neurotrophic factors and corneal nerve regeneration.

Authors:  Marta Sacchetti; Alessandro Lambiase
Journal:  Neural Regen Res       Date:  2017-08       Impact factor: 5.135

10.  RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model.

Authors:  Chae Eun Kim; Hynda K Kleinman; Gabriel Sosne; George W Ousler; Kyeongsoon Kim; Sinwook Kang; Jaewook Yang
Journal:  Sci Rep       Date:  2018-07-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.